Table 6.
Ukraine | Kazakhstan | Azerbaijan | |||||||
---|---|---|---|---|---|---|---|---|---|
Non-COPDN = 909 | COPDN = 30 | p-valuea | Non-COPDN = 882 | COPDN = 63 | p-valuea | Non-COPDN = 898 | COPDN = 35 | p-valuea | |
Any co-morbidity | 42.5% | 56.7% | 0.136 | 26.9% | 50.8% | < 0.001 | 53.8% | 74.3% | 0.023 |
Hypertension | 14.0% | 40.0% | 0.001 | 25.5% | 36.5% | 0.074 | 16.8% | 34.3% | 0.012 |
Diabetes | 3.4% | 6.7% | 0.621 | 3.4% | 7.9% | 0.078 | 5.2% | 8.6% | 0.428 |
Cardiovascular disease | 6.0% | 26.7% | ˂0.001 | 7.8% | 22.2% | 0.001 | 3.5% | 22.9% | ˂0.001 |
Abnormal blood lipids | 4.9% | 13.3% | 0.062 | 11.7% | 15.9% | 0.421 | 1.3% | 0.0% | 1.000 |
Depression | 0.7% | 0.0% | 1.000 | 0.6% | 0.0% | 1.000 | 1.9% | 2.9% | 1.000 |
Anxiety | 0.2% | 0.0% | 1.000 | 0.6% | 0.0% | 1.000 | 2.6% | 5.7% | 0.240 |
Osteoporosis | 0.7% | 0.0% | 1.000 | 1.6% | 3.2% | 0.618 | 0.6% | 0.0% | 1.000 |
Tuberculosis | 0.2% | 6.7% | 0.006 | 2.3% | 0.0% | 0.391 | 1.4% | 2.9% | 1.000 |
Pneumonia | 19.4% | 36.7% | 0.024 | 14.9% | 31.7% | 0.001 | 5.9% | 17.1% | 0.019 |
atwo-sided Pearson Chi-Square test for a comparison between COPD and non-COPD populations
COPD population: respondents with COPD diagnosed by spirometry (post-dose FEV1/FVC < 0.70)
Non-COPD population: respondents without COPD diagnosed by spirometry (post-dose FEV1/FVC ≥ 0.70)